All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Novel prophylactic therapies available before and after transplantation to reduce the risk of GvHD
Bookmark this article
The GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. This interview with Ali Bazarbachi, American University of Beirut, Beirut, LB, was on the topic of novel prophylactic therapies available before and after transplantation to reduce the risk of graft-versus-host disease.
Ali Bazarbachi discusses the evolving treatment landscape of GvHD prophylaxis and treatment. He explains the success of post-transplant cyclophosphamide in the haploidentical setting. He also discusses the results of a study that examined the use of post-transplant cyclophosphamide in the match related/unrelated setting. Ali Bazarbachi concludes by summarizing the results of a study from the Acute Leukaemia Working Party (ALWP) EBMT, that examined the efficacy of anti-thymocyte globulin or post cyclophosphamide to reduce chronic GvHD.
Novel prophylactic therapies available before and after transplantation to reduce the risk of GvHD
Your opinion matters
8 votes - 27 days left ...
Related articles
Newsletter
Subscribe to get the best content related to GvHD delivered to your inbox